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56 The Journal of Thoracic and Cardiobjective: We sought to demonstrate the safety and feasibility of an integrated
oronary revascularization strategy that combines minimally invasive left internal
horacic artery to left anterior descending coronary artery anastomosis with drug-
luting stent implantation to non-left anterior descending coronary artery lesions.
ethods: Over 18 months, 47 consecutive patients with multivessel coronary artery
isease underwent thoracoscopic harvesting of the left internal thoracic artery to
raft the left anterior descending coronary artery. Anastomoses were constructed by
and, off-pump, and under direct vision through a 4-cm non–rib-spreading, muscle-
paring chest incision. Non-left anterior descending coronary artery lesions were
hen treated percutaneously using sirolimus- or paclitaxel-eluting stents. Angio-
raphic follow-up was performed in all patients.
esults: Within the first 90 days of hospitalizations, there were no deaths, myocardial
nfarctions, neurologic events, or wound complications. Forty patients underwent left
nternal thoracic artery to left anterior descending coronary artery grafting, and 7 patients
nderwent left internal thoracic artery to left anterior descending coronary artery/
iagonal sequential grafting for a total of 54 anastomoses. Angiographic patency scores
ere FitzGibbon A 96.2% (52/54) and FitzGibbon A B 100% (54/54). A total of 65
rug-eluting stents were implanted in 61 non-left anterior descending coronary artery
oronary lesions of which 49.1% (30/61) were type B2 or C lesions, including 5 left
ain lesions. Diabetes was present in 53.2% of patients (25/47). At a mean follow-up
ime of 7.0  4.8 months, the target lesion or vessel repeat revascularization rate was
.6% (4/61) for drug-eluting stents and 1.9% (1/54) for left internal thoracic artery to left
nterior descending coronary artery grafting. One anastomosis required balloon dilation,
ut no patients have required repeat coronary artery bypass grafting.
onclusions: Integrated coronary revascularization using drug-eluting stents is
easible and safe. There are sufficient data to justify a randomized comparison of
ntegrated coronary revascularization with standard coronary artery bypass grafting.
ntegrated coronary artery revascularization denotes the intentional combination of
coronary artery bypass grafting with percutaneous coronary artery intervention;
more specifically, minimally invasive left internal thoracic artery (LITA) to left
nterior descending artery (LAD) in conjunction with stenting of non-LAD stenoses.
istorically, the primary rationale for integrated coronary revascularization (ICR) or
vascular Surgery ● May 2006
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Phybrid” revascularization has been to decrease the periproce-
ural morbidity of traditional coronary artery bypass grafting
CABG) in high-risk patients. Since the first report of hybrid
oronary therapy by Angelini and colleagues in 1996,1 there
ave been 10 published series approaching a collective total of
00 patients.2-11 The overall results of these series were re-
ently summarized and discussed by Murphy and colleagues.12
ith the recent introduction of drug-eluting stents (DES) with
lower associated restenosis rate,13 integrated coronary revas-
ularization may be a more durable option than previously
eported for selected patients with multivessel coronary artery
isease. We prospectively collected data on our patients man-
ged by the hybrid approach since its application at our
nstitution.
aterials and Methods
atients
uring the 18-month period between October 2003 and April 2005,
ata from 47 consecutive patients undergoing ICR were prospectively
ntered into a customized database. The group was composed of 34
en (72.3%) and 13 women (27.7%) whose age ranged between 43
nd 90 years (mean, 65.6 years). Thirty-nine of the patients had good
eft ventricular (LV) function (ejection fraction [EF]  50%), 5 had
oderate LV function (35%-49%), and 3 had poor LV function
35% EF). The preoperative demographic and clinical data are
resented in Table 1. The study was approved by the institutional
eview board of Emory University on May 27, 2005.
Coronary angiograms were jointly reviewed by the operating
urgeon and cardiologist before any procedure was performed. All
atients underwent endoscopic atraumatic coronary artery bypass
endoACAB) grafting to graft the left anterior descending (LAD)
oronary artery (with or without the diagonal coronary artery).
ercutaneous coronary intervention (PCI) of the other stenotic
esions generally followed the surgery by 2 to 5 days, but on a few
ccasions preceded the surgery. Patients were considered suitable
or ICR if the LAD was considered graftable and the non-LAD
tenoses were approachable by stenting.
ontraindications to Integrated Coronary
evascularization
he following patient characteristics were considered contraindi-
Abbreviations and Acronyms
DES  drug-eluting stent
EF  ejection fraction
endoACAB endoscopic atraumatic coronary artery
bypass
ICR  integrated coronary revascularization
LAD  left anterior descending coronary artery
LITA  left internal thoracic artery
LV  left ventricular
PCI  percutaneous coronary intervention
TLVR  target lesion repeat revascularizationations for the endoACAB procedure: a nongraftable LAD, a a
The Journal of Thoracicreviously used LITA, previous thoracic surgery involving the left
leural space, chronic lung disease with a forced vital capacity at
second of less than 1.0 liter, and a body mass index greater than
5. The following non-LAD lesion types were believed to be
ontraindications to PCI as part of the ICR approach because of the
igh predicted restenosis rate or technical complexity: chronic
otal occlusions, long lesions requiring multiple stents, a coronary
essel less than 1.5 mm in diameter, saphenous vein graft lesions,
r the presence of fresh thrombus. A creatinine level greater than
.0 was also considered a relative contraindication to ICR.
rocedures
he technical aspects of the endoACAB procedure have been
iscussed in detail but will be outlined briefly here.14,15 The
verall objective of the endoACAB procedure is to graft the LAD,
nd on occasion, the diagonal artery, through a fairly atraumatic
ABLE 1. Demographic and clinical baseline
haracteristics
Patient characteristics (n  47) Value (%)
ge (y)  SD 65.6  11.15 —
ge (y) range 43-90 —
ale/female ratio 34/13 —
moking 17 36.2
ody mass index  SD 31.3  2.9 —
everely obese: BMI  35 9 19.1
iabetes 25 53.2
yperlipidemia 30 63.8
ypertension 28 68.3
hronic pulmonary disease 7 14.9
hronic renal failure 5 10.6
eripheral vascular disease 11 23.4
erebrovascular disease 6 12.8
V ejection fraction  SD 51.2  7.9 —
rior myocardial infarction 14 29.8
rior intervention
PCI 6 12.8
CABG 1 2.1
AD lesion
Type A 0 0.0
Type B1 3 5.6
Type B2 12 22.2
Type C 39 72.2
oronary artery disease
2-vessel 29 61.7
3-vessel 18 38.3
Left main 5 10.6
ngina class (CCS)
I 7 14.8
II 12 25.5
III 24 51.1
IV 4 8.5
D, Standard deviation; BMI, body mass index; LV, left ventricle; PCI,
ercutaneous coronary intervention; LAD, left anterior descending; CABG,
oronary artery bypass grafting; CCS, Canadian Cardiovascular Society.pproach. The patient is induced under general anesthesia, and a
and Cardiovascular Surgery ● Volume 131, Number 5 957
d
W
c
a
(
t
T
p
r
C
a
s
i
i
t
t
L
c
P
s
a
h
T
c
h
l
M
(
t
t
b
r
d
s
u
r
e
e
d
h
p
w
t
u
d
r
t
I
o
l
g
s
p
C
A
t
H
a
p
i
n
f
d
d
t
(
t
g
o
m
w
R
E
w
I
p
f
T
w
L
a
F
d
T
G
L
L
L
T
L
Cardiopulmonary Support and Physiology Vassiliades et al
9
CSPouble-lumen endotracheal tube is inserted for left lung isolation.
ith the left lung collapsed, the LITA is harvested thoracoscopi-
ally using three 5-mm incisions along the left anterior and mid-
xillary lines. A 5-mm, 0-degree telescope with a 3-chip camera
Karl Storz Endoscopy-America, Culver City, Calif) is placed in
he fifth intercostal space through a 5.5-mm port (Snowden Pencer,
ucker, Ga). Carbon dioxide insufflation is introduced through the
ort’s side arm at an intrathoracic pressure of 8 to 10 mm Hg. For
ight-handed surgeons, the endoscopic grasper (Estech, Danville,
alif) is inserted in the seventh intercostal space without a port and
long, monopolar electrosurgery pencil with accompanying
moke evacuator (Valleylab, Boulder, Colo) is placed in the third
ntercostal space, also without a port. The LITA is harvested from
ts origin from the left subclavian artery to the bifurcation at
he level of the sixth rib. The pericardium is opened vertically over
he main pulmonary artery following the anticipated course of the
AD. A long spinal needle is then placed through the anterior
hest wall to identify the exact skin location of the patient’s LAD.
roper identification of the LAD and subsequent selection of the
kin incision allows the surgeon to subsequently perform the
nastomosis without rib spreading. In all patients, unfractionated
eparin (400 IU/kg body weight) is administered intravenously.
he LITA to LAD  diagonal anastomosis is constructed using
ommonly adopted off-pump techniques. The preexisting LITA
arvesting ports serve as the entry points for an epicardial stabi-
izer (Guidant, Santa Clara, Calif; Estech, Danville, Calif;
edtronic, Minneapolis, Minn) and carbon dioxide mister/blower
Medtronic). Intracoronary shunts are used selectively. Transit-
ime Doppler (Medi-stim AS, Medtronic) examination of the anas-
omosis is performed to verify graft patency.16 Patients are extu-
ated in the operating room or immediately on arrival to the
ecovery unit whenever possible.
The order of the 2 procedures (endoACAB and PCI) is largely
etermined by the patient’s coronary anatomy and is a joint deci-
ion between the surgeon and referring cardiologist. Most patients
ndergo the surgical procedure first because of the logistical issues
elating to anticoagulation. The patient is administered 81 mg of
nteric-coated aspirin daily before operation. Four hours after the
ndoACAB procedure, the patient is started on clopidogrel 75 mg
aily. The PCI with stenting is usually performed in the same
ospitalization within 48 hours of endoACAB. Depending on the
atient, PCI may be delayed, with the patient returning several
eeks later.
All patients underwent angiographic examination of the LITA
o LAD diagonal grafts. Before stenting, patients received either
ABLE 2. Graft patency scores
raft procedure Patients Anastomoses
FitzGibbon
scores
A B O
ITA to LAD 40 40 38 2 0
ITA to LAD and diagonal 6 12 12 0 0
ITA to LAD 2 1 2 2 0 0
otal 47 54 52 2 0
ITA, Left internal thoracic artery; LAD, left anterior descending.nfractionated heparin (100 IU/kg body weight) or the appropriate s
58 The Journal of Thoracic and Cardiovascular Surgery ● Mayose of bivalirudin intravenously. If patients were not already
eceiving a maintenance dose of clopidogrel, they were adminis-
ered a loading dose of 300 to 600 mg. Platelet glycoprotein
Ib/IIIa receptor inhibitors were given at the discretion of the
perator. Patients received lifelong aspirin and clopidogrel for at
east 3 to 6 months after DES implantation. All coronary bypass
rafts and dilated coronary vessels, before and after stenting, were
cored using computer processing of still images in multiple
lanes.
linical Definitions and Follow-up
complete follow-up was performed in all 47 patients either by
elephone or in-person with April 30, 2005, as the end point.
ospital and clinic records were reviewed from Emory University
nd outside treatment centers as appropriate. The mean follow-up
eriod was 7.0  4.8 months. Angiographic follow-up beyond the
nitial procedure was obtained only if clinically indicated and was
ot routinely performed in all patients. The events analyzed in the
ollow-up report included death (cardiac and noncardiac), myocar-
ial infarction (Q-wave and non-Q-wave), neurologic event (car-
iovascular accident or transit ischemic attack), restenosis, stent
hrombosis, and target lesion or vessel repeat revascularization
TLVR). TLVR was defined as the need for repeat revasculariza-
ion, either surgical or percutaneous) secondary to stenosis 50% or
reater within the stent, anywhere within the graft or anastomosis,
r within 5-mm borders proximal or distal to the stent or anasto-
osis at the follow-up angiogram. Major adverse cardiac events
ere defined as death, myocardial infarction, and TLVR.
esults
ndoACAB preceded stenting in 42 of 47 patients (89.4%)
ith a mean interval between procedures of 3.5  1.3 days.
n the 5 patients (10.6%) undergoing PCI first, the endoACAB
rocedure was performed while the patient remained on
ull-dose clopidogrel during a separate, later hospitalization.
he mean time from PCI to endoACAB for these patients
as 71.7  41.1 days. Forty of the total 47 patients had a
ITA to LAD graft. Six patients received a LITA to LAD
nd diagonal sequential graft, and 1 patient received a
igure 1. Comparison of lesion type between bypass grafts (LAD
istribution) and stents (non-LAD distribution).equential LITA to 2 locations on the LAD. A total of 54
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Pnastomoses were constructed in 47 patients. The angio-
raphic patency scores for the coronary bypass grafts were
itzGibbon A of 96.2% (52/54) and FitzGibbon A  B of
00% (54/54), with the complete data provided in Table 2.
The types of coronary lesions treated are illustrated in
igure 1. Coronary lesions treated surgically tended to be
omplicated, whereas stented lesions were more uniformly
istributed between the continuum of lesion types. A total
f 65 stents (41 paclitaxel-eluting [63.1%], 23 sirolimus-
luting [48.9%], and 1 bare metal stent [1.5%]) were im-
lanted in 61 non-LAD coronary lesions (mean of 1.1 stents
er lesion and 1.4 stents per patient) of which 49.1% (30/61)
ere type B2 or C lesions, including 5 left main lesions.
eview of the angiograms from all 47 patients revealed that
ll but 2 patients (95.7%) were completely revascularized.
he 2 patients who remain incompletely revascularized are
n 82-year-old woman with an untreated 80% obtuse mar-
inal lesion and a 68-year-old man with an untreated 70%
eft ventricular branch, both of whom were elected by their
ardiologists to treat medically.
The predicted mortality for standard CABG for the entire
ohort of 47 patients was calculated at a mean risk of 5.8%
6.1% (range 0.6%-33.7%) using the Society of Thoracic
urgeons risk model.16 The risk of permanent stroke was
stimated to be 4.1%  2.9%. Two patients had bleeding
nto the left pleural space requiring a second chest tube
nsertion and a blood transfusion. Neither of these patients
equired reexploration. Two patients had postoperative peri-
arditis that responded well to oral steroids. Thirty-nine
atients (83.0%) were extubated within 90 minutes of the
onclusion of the operation. The in-hospital transfusion rate
as 19.1% (9/47). New-onset atrial fibrillation occurred in
of 45 patients (15.6%). The mean hospital length of stay
tarting from the day of the first procedure was 4.1  1.8
ays (range 3-17 days).
Clinical follow-up was available in all patients. The
umulative major adverse cardiac events rate was 10.6%
5/47). Four cases of TLVR occurred: edge restenoses (3
ases) and in-stent restenosis (1 case). Each case was treated
y repeat stenting using DES. The 1 case of TLVR occurred
n a patient 2 days after endoACAB during angiography for
he planned PCI of the non-LAD lesions. The patient was
ound to have a 70% stenosis at the site of the LITA to LAD
nastomosis, which was ballooned open using 2 atmo-
pheres of pressure without the need for stenting.
onclusions
he rationale for choosing integrated coronary revascular-
zation over PCI or CABG alone stems from a number of
bservations: (1) the mean age and risk score of patients
ith multivessel coronary artery disease continues to in-
rease every year;17 (2) the LAD is, arguably, the most
mportant of the 3 coronary branches, supplying 50% to
The Journal of Thoracic0% of the ventricular mass and twice the mass of the
ircumflex or right coronary distributions; (3) the LITA has
een clearly shown to be more effective than PCI with
espect to event-free survival, relief of angina, and long-
erm patency;18,19 (4) conventional bypass surgery carries
ultiple potential complications attributed to both the ster-
otomy and the use of the cardiopulmonary bypass circuit,
ncluding neurocognitive impairment;20 (5) the early reste-
osis rate of non-LAD vessels after PCI (using DES) may
ot be significantly different from the early occlusion rate of
aphenous vein grafts. Perrault and colleagues21 found the
-month occlusion rates of saphenous vein grafts to be
etween 14.8% and 15.6%. Similar results were found by
un and colleagues22 with vein graft occlusion rates be-
ween 17.6% and 21.7% at 6 months.
The present report has some limitations: (1) It is a
etrospective study, (2) not all patients have had midterm
ngiographic follow-up, and (3) clinical follow-up is limited
o 7 months. Despite these limitations, this report represents
large cohort of patients with multivessel disease treated
ith ICR using DES. The main findings that can be drawn
rom this report are as follows:
● Combining DES with endoACAB seems to be safe
and efficacious in early follow-up. Similar to off-
pump coronary artery bypass surgery performed through
a sternotomy, the avoidance of cardiopulmonary by-
pass seems to be an advantage in many subgroups of
patients with certain comorbidities, namely, periph-
eral vascular disease, renal insufficiency, advanced
age, diabetes, and poor ventricular function.22 In ad-
dition, endoACAB does not involve any manipulation
of the aorta; the reported incidence of cerebrovascular
complications is less than 1%.2-11 Unlike off-pump
coronary artery bypass surgery, however, endoACAB
inflicts considerably less chest wall trauma. There is
no division of bone or major thoracic musculature,
which can cause considerable disability and pain after
a sternotomy or traditional anterior thoracotomy. The
fact that the incision is essentially a large thoracos-
copy port provides an extremely low risk of wound
complications particularly for the obese or diabetic
patient. The procedure-specific morbidity associated
with the traditional minimally invasive direct coronary
artery bypass has not been seen with the endoACAB
procedure.23
● ICR can be safely performed in either sequence of
procedures. In our experience, we prefer to graft the
LAD first, to avoid operating on the patient on full-
dose clopidogrel. However, in the 5 patients (10.6%)
undergoing PCI first, intraoperative or postoperative
bleeding was not increased. In each of these cases, the
patients presented with a greater than 95% lesion of a
large, dominant RCA. Revascularization of the RCA
and Cardiovascular Surgery ● Volume 131, Number 5 959
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CSPbefore the LAD seemed to be the safer approach. It is
conceivable that patients could undergo simultaneous
LITA to LAD grafting and stenting of the non-LAD
targets in a “hybrid” catheterization/operating room.
At the completion of the anastomosis, the clopidogrel
could be loaded, recognizing that surgical hemostasis
could be achieved before the full anticoagulation ef-
fects were seen clinically.
● The hybrid approach may be the preferred approach in
patients with coronary artery disease too complicated
for multivessel PCI or patients with comorbidities too
extensive for low-risk conventional bypass surgery. In
our series, 23% of the patients (11/47) had a Society
of Thoracic Surgeons predicted mortality of more than
20% and a predicted risk of stroke of 10% to 20%.
● The rate of TVR for DES of the non-LAD coronary
arteries in this series compares well with the reported
outcome data of the randomized clinical trials of DES
versus bare metal stents, particularly when the high
incidence (53.2%) of diabetes in our series is consid-
ered. In addition, a rough comparison of our cohort of
47 patients with the patients in the Sirius and Taxus I
and II trials reveals a slightly more complex lesion set,
signifying low DES TVR rates with even “real-world”
lesions.24-26 Previously a significant limitation of the
ICR approach, the DES TVR results present a more
compelling argument for the hybrid concept.
At present, most centers are not performing hybrid cor-
nary revascularization or are treating less than 5% of the
opulation with coronary artery disease using this approach.
f the ICR approach to coronary artery disease intervention
s to grow, several key issues will need to be resolved. At
resent, the total cost of the hybrid procedure exceeds the
ost of CABG in most centers, although presently, hospitals
re able to collect reimbursement to cover the additional
osts. Performing more procedures and further integrating
he catheterization laboratory with the operating room, ei-
her as a combined procedure room or with coordinated
rotocols, is likely to drive efficiency. In addition, the
ybrid procedure may be economically viable if it results in
ower postprocedural adverse events and reintervention
ates. Despite the lower restenosis rates of DES, the ICR
pproach is limited by the presence or absence of coronary
natomy amenable to stenting. Chronic total occlusions,
ong lesions requiring multiple stents, the presence of dia-
etes, vessels less than 1.5 mm in diameter, and bifurcation
esions continue to be problematic for the interventional
ardiologist.
In summary, integrated revascularization requires close
ollaboration between the cardiologist and the surgeon be-
ause careful planning of the strategy and timing are nec-
ssary. The potential advantages of the hybrid approach are
educed short-term clinical events, such as death, stroke,
60 The Journal of Thoracic and Cardiovascular Surgery ● Mayyocardial infarction, and infection, as well as a superior
uality of life as a result of a quicker return to a “normal”
ifestyle. The potential disadvantages of ICR are a higher
ropensity to incompletely revascularize the patient, a
igher reintervention rate related primarily to stent resteno-
is, the cost of the procedure, requiring the use of both
perating room and catheterization laboratory resources,
nd the possible negative effects on the long-term survival
f these patients.27 The procedure also requires special
xpertise in the endoACAB operation or in a similar mini-
ally invasive bypass operation. However, without data
rom a large prospective, randomized trial comparing con-
entional bypass surgery with the hybrid approach, the
otential advantages and disadvantages of ICR remain the-
retic and largely unproven.28
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iscussion
r. Cohen. Tom, that was a nice paper and I enjoyed reading your
anuscript. I also really enjoyed seeing a video of your procedure
ecently on the surgical forum and would certainly recommend it
o anybody who is interested in this operation.
The concept of the integrated coronary artery revascularization,
he so-called hybrid operation, has been around for sometime. It
ffers the combination of a truly minimally invasive internal
ammary artery to the LAD followed by drug-coated stents in any
emaining lesions to achieve complete coronary revascularization.
r. Vassiliades and his group are to be congratulated for their
uccess with the endo-ACAB operation and for their excellent
hort-term clinical results. Having said that, one can’t help but
onder where this procedure will take its place in the continuum
f coronary revascularization procedures. After all, it requires
earning specialized and new surgical skills, increased collabora-
ion between cardiologists and cardiac surgeons, the potential for
wo or more hospitalizations, and as you’ve said followup is t
The Journal of Thoracicxtremely short. Now the rationale for this operation is based on
ome important assumptions that I’d like to discuss. The first is
hat a minimally invasive non-rib spreading left anterior approach
ith an off-pump anastomosis carries considerably less morbidity
han an on-pump operation via sternotomy incision in selected
atients. I agree with that. It’s also suggested that this may be
xtremely suitable for high-risk patients. In fact, the predicted
ortality for standard CABG in this study’s cohort was a mean of
.8% using the STS risk model. I thought that was pretty high and
hat brings me to my first question. When I looked at the demo-
raphics of your patient group, they actually seemed to be pretty
ypical or actually even low risk. The mean age was 65. The mean
jection fraction was 51%. Sixty percent of your patients had
wo-vessel disease, and you had what I thought to be the usual
mount of diabetes, hypertension, pulmonary disease, cerebrovas-
ular disease and renal failure. Given . . . (end of cassette) . . . and
or heart surgery candidates, candidates for this operation, aren’t
hey patients who actually have less coronary disease than most of
he patients that we see for coronary bypass grafting?
Dr. Vassiliades. Well, to speak to the STS model, I was a bit
urprised too. As you know, if you go to the STS website, you can
nteractively use their risk model and this is the data that was
ntered and this is the information we got, so I really don’t what
lse to say about that other than it does seem pretty high to me as
ell. You wouldn’t expect an 8% predicted mortality on that group
f patients. So I don’t necessarily make any claims that clearly
here is improvement in mortality. We are just at this point dem-
nstrating that it can be performed safely.
The second part of your question related to, don’t these patients
eally have less coronary disease. I think that if you look, 60% of
he patients only had two-vessel disease. I think because we are
arly in exploring the logistics of dealing with drug eluting stents,
iven the special anticoagulation needs of that particular stent, that
e tended to be more conservative and I think that as we are
oving along we are becoming much more aggressive and the
ardiologists are becoming much more aggressive in feeling com-
ortable in proceeding with more complicated lesions. I think that
s part of an early study, yes, we deliberately selected patients that
ad perhaps two-vessel or less complicated coronary artery disease
ith respect to stenting.
Dr. Cohen. Another assumption that you made in your manu-
cript, and it was an important one in justifying this procedure, it
ays the early patency rate of drug eluting stents in non-LAD
esions is no longer significantly different than that of saphenous
ein grafts. This justified the use of PTCA for revascularization of
on-LAD vessels in your series. The manuscript references the
arry(?) trial which was performed in the early 1990s, published
n 2000, well before drug eluting stents became available. I really
ouldn’t find a reference in that reference that really compared the
atency rate of stents with vein grafts. Is there really current data
hich accurately compares the performance of drug eluting stents
ith that of current saphenous vein grafting techniques?
Dr. Vassiliades. No, there is not, and that is one of the
remendous pieces of information that could be gained by doing a
andomized trial. There is a study ongoing that is being funded by
oston Scientific looking at drug eluting stenting in all three
essels compared to standard bypass surgery and we’ll get some of
hat information, but the assumption there is a very broad one.
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CSPhere has never been a head to head comparison. One generally is
ware of the fact that the occlusion rate of vein grafts various
nywhere from 10 to 20% in the first year and then looking at the
wo-year data of the _____-4 results showing somewhere in the 10
o 12% range, but again these are apples and oranges. The lesion
ets are different.
Dr. Cohen. Finally, yesterday in his president address our
resident described what he called the hope cycle for emerging
echnology and I thought that this procedure fit very nicely, where
here is sort of a technology trigger and then you get this peak of
nflated expectations followed by a trough of disillusionment. My
oncern is that this is an operation which, though innovative, is
nly applicable to a small number of patients with complex LAD
isease and maybe a couple other coronary lesions. So having sort
f put yourself in the middle, what’s your strategy for convincing
urgeons that we should stop short of completely revascularizing
atients ourselves and at the same time for convincing interven-
ional cardiologists that they can keep us in the loop at all?
Dr. Vassiliades. I think the data are there. The problem is that
e are operating in a world where not everyone necessarily prac-
ices the way the data have directed us to practice and I think that
here is little disagreement of the benefit of LIMA to the LAD and
ou could argue that is probably one of the last things that the62 The Journal of Thoracic and Cardiovascular Surgery ● Mayot get rid of that. Let’s just improve that operation and make it
ess traumatic. That’s the reason patients are not necessarily being
eferred for surgery. It’s not just the cardiologists. Patients are sort
f demanding less invasive procedures. Now does that mean we
hould alter our procedure based on what the physical therapy
ants? Well, it also has to do with whether or not we think it’s
ight for the patient. I think it’s just a difference of opinion. I think
hat this is a perfect opportunity to build a niche and create a much
arger niche in terms of revascularization in an area in many places
hat is rapidly dying off and I think the LIMA to the LAD should
e preserved and such ways to be able to make it better and I think
iven the fact that most patients are presenting with three-vessel
isease, I think the hybrid approach is a very good way to explore
t, but really the driving mechanism has to be good data. If we can
ome day get funding for a good randomized trial, I think that
ould help a lot.
Dr. Cohen. I think one thing that is for certain is your results
re excellent. As long as you can continue to show excellent results
ith anything that you do as innovative you are going to have a
ood chance.
I really appreciate it and I appreciate the opportunity of the
oor.urgeon has to offer in terms of revascularization surgery, so let’s Dr. Vassiliades. Thank you for your comments.2006
